As our industry continues to rapidly evolve, product diversity, world-class research and supply-chain advancements are becoming increasingly important. Our sharp focus on innovation at the global stage is accomplished through ongoing strategic investment and ownership of leading research, partnerships with disruptive brands and organizations, and acquisitions.

Spectrum Therapeutics logo

Spectrum Therapeutics is focused on developing and researching clinically-ready, whole-plant cannabis drug formulations and dose delivery systems. The ultimate goal is to validate diversified treatment options for Canadians and for patients and consumers in other jurisdictions where treatment with cannabis is federally legal. The foundation of our research and development plan is to improve the quality of life and health of those suffering from acute and chronic illnesses. The proper formulation of cannabinoids means the opportunity to improve a number of common complaints and ailments, like pain, appetite stimulation, and sleep quality. Medical cannabis is also used to manage common diseases such as dementia, Alzheimer’s, autism, autoimmune diseases like Crohn’s disease and colitis, and fibromyalgia.

The Canopy Innovation Lab is supported by the Dealer’s License Area in Smiths Falls which allows the company to push product development and R&D beyond the limits of the Access to Cannabis for Medical Purposes Regulations. As new product types join the legally permissible framework, it’s always helpful to have a head start. Whether through in-house innovation or strategic partnerships, the Canopy Innovation Lab will play a pivotal role driving Canopy Growth’s aggressive innovation agenda.

Storz & Bickel are designers and manufacturers of the only medically approved vaporizers in the world, most notably the Volcano Medic and the Mighty Medic.  Storz & Bickel began operations in 2000 and have spent the last two decades developing an automated and internationally certified factory, achieving ISO 13485 certification in 2009. An ISO 13485 certification means that the Storz and Bickel’s facilities have been scrutinized by external auditors and found to be compliant with all requirements needed to produce medical devices.

Its IP portfolio will improve Canopy Growth’s existing vaporizer design operations. Drawing on talent from Ottawa’s tech ecosystem, Canopy Growth has for the past 12 months assembled and lead a team of hardware and software engineers developing a line of vaporizing devices targeting the needs of both recreational and medical markets, as the Company prepares for the next wave of federally regulated products in Canada beyond dried flower and edible cannabis oils, as well as international opportunities.

Intellectual Property and R&D advancements achieved by ebbu’s team apply directly to Canopy Growth’s hemp and THC-rich cannabis genetic breeding program and its cannabis-infused beverage capabilities. In addition, ebbu’s IP portfolio will contribute to the clinical formulations program executed by Canopy Health Innovations. Canopy Growth operates a rapidly emerging, field-scale hemp operation based in Saskatchewan and by applying ebbu’s IP, the Company has the potential to vastly reduce the cost of CBD production, a sought-after cannabinoid in both the wellness and medical spaces.

Battelle and Canopy Growth work together to advance knowledge surrounding cannabis in support of medical research and novel product development. Canopy Growth and Battelle completed the rigorous federal approval process required to import cannabis products into the United States and since October 9th, the organizations have completed multiple product transfers to Battelle’s secure research facilities pursuant to United States Drug Enforcement Agency approvals. For decades, Battelle scientists have developed methods for testing a variety of controlled substances as well as employing analytical chemistry services for government and private industry. Notably, product transfers have consisted of a variety of cannabis form factors, including dried cannabis and Canopy Growth’s precisely dosed Softgels.

Every day, the people of Battelle apply science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers. Headquartered in Columbus, Ohio since its founding in 1929, Battelle serves the national security, health and life sciences, and energy and environmental industries.

Apollo Applied Research is dedicated to identifying the most effective strains of medical cannabis for patients suffering with chronic pain as well as many other medical conditions. Apollo offers an evidence based approach to treating patients with medical cannabis by running two of Canada’s largest medical cannabis studies. Apollo’s continuing research helps better evaluate the benefits of medical cannabis and allows Apollo to discover and better understand the most effective strains for each condition. Apollo has been conducting clinical research on chronic pain since 2014 and in March of 2016 Apollo launched its newest study analyzing the effects of medical cannabis on patients with PTSD. Apollo’s research has been published in multiple medical journals and is regularly called upon to present at medical seminars and conferences including the Clinical Research Association of Canada.

Canopy Growth is an early investor in Scientus Pharma, a vertically-integrated biopharmaceutical Licensed Dealer focused on developing and commercializing pharmaceutical-grade cannabinoid derivative products. Scientus Pharma has the ability to wholesale, buy, process and sell cannabinoid derivatives, from and to Licensed Producers, as well as international markets. Canopy partially owns approximately 9.8% of Scientus Pharma.